Article
Biochemistry & Molecular Biology
Liurong Liu, Huihui Yao, Xin Zhou, Junjie Chen, Guoliang Chen, Xinyu Shi, Guanting Wu, Guoqiang Zhou, Songbing He
Summary: miR-15a-3p positively regulates ferroptosis in CRC by targeting GPX4, leading to increased levels of reactive oxygen species and malondialdehyde accumulation with overexpression, while reducing sensitivity to erastin and GPX4 with suppression.
MOLECULAR CARCINOGENESIS
(2022)
Article
Cell Biology
Dan Song, Qian Zhang, Hao Zhang, Liangliang Zhan, Xinchen Sun
Summary: The study reveals that miR-130b-3p is upregulated in colorectal cancer (CRC) tissues and cells and can be detected in the feces of CRC patients. Inhibition of miR-130b-3p suppresses CRC cell proliferation and tumor growth in vivo. The mechanism involves direct targeting of chromodomain helicase DNA binding protein 9 (CHD9) by miR-130b-3p.
Article
Biochemistry & Molecular Biology
Ryutaro Yasudome, Naohiko Seki, Shunichi Asai, Yusuke Goto, Yoshiaki Kita, Yuto Hozaka, Masumi Wada, Kan Tanabe, Tetsuya Idichi, Shinichiro Mori, Takao Ohtsuka
Summary: In this study, we identified a miRNA, miR-139-3p, that plays a tumor-suppressive role in colorectal cancer (CRC) by inhibiting cancer cell malignant transformation and AKT phosphorylation. Through in silico analysis and gene expression assays, we identified 29 potential targets regulated by miR-139-3p in CRC cells. We also discovered aberrant expression of Keratin 80 (KRT80) in CRC clinical specimens and found that reducing KRT80 expression suppressed CRC cell malignant transformation and AKT phosphorylation. Additionally, the expression of hexokinase-2 (HK2) was reduced in cells with decreased KRT80 or miR-139-3p expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Weitong Zhang, Zhenfen Wang, Guohao Cai, Ping Huang
Summary: This study revealed that circ_DOCK1 plays a role in colorectal cancer progression by regulating the miR-132-3p/USP11 axis, with circ_DOCK1 knockdown inhibiting cell growth and metastasis while promoting apoptosis.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Yu Liu, Wentao Tang, Li Ren, Tianyu Liu, Meng Yang, Ye Wei, Yijiao Chen, Meiling Ji, Guosong Chen, Wenju Chang, Jianmin Xu
Summary: miR-500a-3p is downregulated in CRC and inhibits cancer cell proliferation and glycolysis by targeting CDK6.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Clinical Neurology
Francesca De Vito, Alessandra Musella, Diego Fresegna, Francesca Romana Rizzo, Antonietta Gentile, Mario Stampanoni Bassi, Luana Gilio, Fabio Buttari, Claudio Procaccini, Alessandra Colamatteo, Silvia Bullitta, Livia Guadalupi, Silvia Caioli, Valentina Vanni, Sara Balletta, Krizia Sanna, Antonio Bruno, Ettore Dolcetti, Roberto Furlan, Annamaria Finardi, Valerio Licursi, Jelena Drulovic, Tatjana Pekmezovic, Clorinda Fusco, Sara Bruzzaniti, Eran Hornstein, Antonio Uccelli, Marco Salvetti, Giuseppe Matarese, Diego Centonze, Georgia Mandolesi
Summary: MiR-142-3p is a potential negative prognostic CSF marker of MS, showing positive correlations with clinical progression, IL-1 beta signalling, and synaptic excitability. Treatment with DMF, a disease-modifying therapy, had a superior effect on patients with low levels of miR-142-3p.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
(2022)
Article
Cell Biology
Rui Qian, Xinli Niu, Yinghui Wang, Zhi Guo, Xuyi Deng, Zhenhua Ding, Meijuan Zhou, Haijun Deng
Summary: MALT1 is highly upregulated in colorectal cancer and plays a crucial role in cell proliferation and migration. MiR-375 and miR-365a-3p inhibit NF-κB activation by targeting MALT1, affecting the progression of CRC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Junfeng Ying, Guanglan Liu, Xinguo Zhu
Summary: This study investigated the impact of circ_0007385 on colorectal cancer (CRC) cell malignant behaviors and revealed its potential mechanism. Functional experiments confirmed the role of hsa_circ_0007385 in CRC. Further analysis revealed the relationship between hsa_circ_0007385 and miRNAs. A xenograft mouse model demonstrated the influence of hsa_circ_0007385 on CRC growth and metastasis.
BIOCHEMICAL GENETICS
(2023)
Article
Oncology
Masamichi Hayashi, Suguru Yamada, Keisuke Kurimoto, Hiroshi Tanabe, Sho Hirabayashi, Fuminori Sonohara, Yoshikuni Inokawa, Hideki Takami, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera
Summary: miR-23b-3p is found to function as an oncogenic microRNA in HCC cell lines. Overexpression of miR-23b-3p in resected HCC tissues is a significant prognostic factor of overall survival. Both MICU3 and AUH may be candidate gene targets of miR-23b-3p.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Zizhen Si, Lei Yu, Haoyu Jing, Lun Wu, Xidi Wang
Summary: In this study, it was found that ZNF561-AS1 promotes CRC progression via the miR-26a-3p/miR-128-5p-SRSF6 axis. This study provides new insights into the role of ZNF561-AS1 in CRC.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Yuto Hozaka, Yoshiaki Kita, Ryutaro Yasudome, Takako Tanaka, Masumi Wada, Tetsuya Idichi, Kan Tanabe, Shunichi Asai, Shogo Moriya, Hiroko Toda, Shinichiro Mori, Hiroshi Kurahara, Takao Ohtsuka, Naohiko Seki
Summary: In this study, a novel miRNA expression signature of colorectal cancer was established based on RNA-sequencing, revealing the tumor-suppressive role of miR-490-3p and its regulation of multiple oncogenic targets in CRC cells. The expression levels of IRAK1, FUT1, and GPRIN2, among the targets identified, significantly predicted the 5-year overall survival of colorectal cancer patients, highlighting the potential prognostic value of these miRNA-regulated genes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, Research & Experimental
Sepideh Razi, Asieh Sadeghi, Zeynab Asadi-Lari, Kevin J. Tam, Elham Kalantari, Zahra Madjd
Summary: The study found a significant negative correlation between DCLK1 expression and miR-137 and miR-15a levels in colorectal cancer. DCLK1 may serve as a marker for colorectal cancer stem cells and potentially play a critical role in tumor diagnosis and treatment.
CLINICAL AND EXPERIMENTAL MEDICINE
(2021)
Article
Oncology
Zhichao Jin, Baoxinzi Liu, Bofan Lin, Ran Yang, Cunen Wu, Weiwei Xue, Xi Zou, Jun Qian
Summary: The long non-coding RNA RP9 pseudogene (RP9P) promotes colorectal cancer progression by regulating the miR-133a-3p/FOXQ1 axis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Guifeng Zhang, Zhenhua Liu, Jiangming Zhong, Li Lin
Summary: The study revealed that circRNA ACAP2 contributes to the progression and radioresistance of colorectal cancer by promoting cell proliferation, migration, invasion, and inhibiting apoptosis. This effect is partly mediated through targeting the miR-143-3p/FZD4 axis and modulating the Wnt/β-catenin signaling pathway in CRC cells.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Multidisciplinary Sciences
Erica Costantini, Bruna Sinjari, Pamela Di Giovanni, Lisa Aielli, Sergio Caputi, Raffaella Muraro, Giovanna Murmura, Marcella Reale
Summary: This study aimed to evaluate the involvement of selected miRNAs in different stages of periodontitis and their relationship with the levels of inflammatory mediators in gingival crevicular fluid (GCF). The results showed that miRNA-103a-3p, miRNA-23a-3p, miRNA-15a-5p, and miRNA-223-3p were significantly upregulated in periodontitis patients, and miRNA-23a-3p, miRNA-103a-3p, and miRNA-423-5p levels differed significantly according to disease stages.
SCIENTIFIC REPORTS
(2023)
Article
Gastroenterology & Hepatology
Berbel L. M. Ykema, Lisanne S. Rigter, Manon C. W. Spaander, Leon M. G. Moons, Tanya M. Bisseling, Berthe M. P. Aleman, Evelien Dekker, Wieke H. M. Verbeek, Ernst J. Kuipers, Jan Paul de Boer, Pieternella J. Lugtenburg, Cecile P. M. Janus, Eefke J. Petersen, Judith M. Roesink, Richard W. M. van der Maazen, Gerrit A. Meijer, Michael Schaapveld, Flora E. van Leeuwen, Beatriz Carvalho, Petur Snaebjornsson, Monique E. van Leerdam
Summary: The study evaluated clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in Hodgkin's lymphoma (HL) survivors who had undergone abdominal radiotherapy and/or procarbazine treatment. Colorectal neoplasia in HL survivors differs from average-risk controls, with AN primarily classified based on polyp size (>=10 mm) and longer follow-up between HL diagnosis and colonoscopy associated with a higher prevalence of AN.
DIGESTIVE ENDOSCOPY
(2022)
Article
Oncology
Roel M. M. Bogie, Chantal M. C. le Clercq, Quirinus J. M. Voorham, Martijn Cordes, Daoud Sie, Christian Rausch, Evert van den Broek, Sara D. J. de Vries, Nicole C. T. van Grieken, Robert G. Riedl, Prapto Sastrowijoto, Ernst-Jan Speel, Rein Vos, Bjorn Winkens, Manon van Engeland, Bauke Ylstra, Gerrit A. Meijer, Ad A. M. Masclee, Beatriz Carvalho
Summary: PCCRCs are more commonly located proximally, non-polypoid appearing, early stage, and poorly differentiated compared to DCRCs. They also show significantly less 18q loss and are more commonly CIMP high and MSI. Molecular features associated with sessile serrated lesions and non-polypoid colorectal neoplasms may contribute to the development of PCCRCs.
BRITISH JOURNAL OF CANCER
(2022)
Article
Gastroenterology & Hepatology
Manon de Krijger, Beatriz Carvalho, Christian Rausch, Anne S. Bolijn, Pien M. Delis-van Diemen, Marianne Tijssen, Manon van Engeland, Nahid Mostafavi, Roel M. M. Bogie, Evelien Dekker, Ad A. M. Masclee, Joanne Verheij, Gerrit A. Meijer, Cyriel Y. Ponsioen
Summary: The excessive risk of colorectal carcinoma (CRC) in patients with both primary sclerosing cholangitis and inflammatory bowel disease (IBD) was not explained by an extensive screen of copy number aberrations, mutations, microsatellite instability, and CpG island methylator phenotype status when compared with patients with IBD-CRC and sporadic CRC.
INFLAMMATORY BOWEL DISEASES
(2022)
Review
Gastroenterology & Hepatology
Zheng Feng, Cary J. G. Oberije, Alouisa J. P. van de Wetering, Alexander Koch, Kim A. D. Wouters, Nathalie Vaes, Ad A. M. Masclee, Beatriz Carvalho, Gerrit A. Meijer, Maurice P. Zeegers, James G. Herman, Veerle Melotte, Manon van Engeland, Kim M. Smits
Summary: A systematic literature search revealed that major requirements for the development of clinically relevant diagnostic CRC DNA methylation markers are often lacking. To avoid research waste, clinical needs, intended biomarker use, and independent validation should be better considered before study design. Additionally, improved reporting quality would facilitate meta-analysis, increasing the level of evidence and enabling clinical translation.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
(2022)
Article
Oncology
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S. M. E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B. A. G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, Daniela S. Thommen
Summary: This study established PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. The biomarker showed high sensitivity and specificity, and had a high negative predictive value in identifying patients without clinical benefit. Additionally, high levels of PD-1T TILs were associated with longer progression-free and overall survival.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Kris G. Samsom, Luuk J. Schipper, Paul Roepman, Linda J. W. Bosch, Ferry Lalezari, Elisabeth G. Klompenhouwer, Adrianus J. de Langen, Tineke E. Buffart, Immy Riethorst, Lieke Schoenmaker, Daoin Schout, Vincent van der Noort, Jose G. van den Berg, Ewart de Bruijn, Jacobus J. M. van der Hoeven, Hans van Snellenberg, Lizet E. van der Kolk, Edwin Cuppen, Emile E. Voest, Gerrit A. Meijer, Kim Monkhorst
Summary: This study aimed to evaluate the feasibility and efficacy of whole-genome sequencing (WGS) in routine clinical practice. The results showed that WGS can be successfully applied to patients with metastatic cancer, providing comprehensive genomic profiling for the majority of patients and identifying actionable biomarkers and treatment options.
JOURNAL OF PATHOLOGY
(2022)
Article
Gastroenterology & Hepatology
Myrtle F. Krul, Marloes A. G. Elferink, Niels F. M. Kok, Evelien Dekker, Iris Lansdorp-Vogelaar, Gerrit A. Meijer, Iris D. Nagtegaal, Emilie C. H. Breekveldt, Theo J. M. Ruers, Monique E. van Leerdam, Koert F. D. Kuhlmann
Summary: The nationwide CRC screening program in the Netherlands, started in 2014, has shown a significant reduction in the incidence of stage II and IV CRC. Patients with screen-detected CRCs had improved survival and less extensive disease compared to clinically detected cases.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Oncology
Iris van 't Erve, Jamie E. Medina, Alessandro Leal, Eniko Papp, Jillian Phallen, Vilmos Adleff, Elaine Jiayuee Chiao, Adith S. Arun, Karen Bolhuis, John K. Simmons, Aanavi Karandikar, Kenneth C. Valkenburg, Mark Sausen, Samuel Angiuoli, Robert B. Scharpf, Cornelis J. A. Punt, Gerrit A. Meijer, Victor E. Velculescu, Remond J. A. Fijneman
Summary: The study demonstrates that accurate monitoring of treatment response using ctDNA can be achieved in a tumor tissue-independent manner by combining cfDNA and patient-matched WBC genomic DNA analysis. This approach prevents false-positives caused by germline or hematopoietic variants and provides more predictive information on overall survival compared to standard radiological evaluation. Additionally, ctDNA analysis reveals potential therapy resistance mutations in a significant portion of patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Pathology
Astrid Kramer, Ed Schuuring, Daan C. L. Vessies, Paul van der Leest, Maartje J. Geerlings, Pim Rozendal, Mirthe Lanfermeijer, Theodora C. Linders, Leon C. van Kempen, Remond J. A. Fijneman, Marjolijn J. L. Ligtenberg, Gerrit A. Meijer, Daan van den Broek, Valesca P. Retel, Veerle M. H. Coup
Summary: This study developed a micro-costing framework for consistent cost calculation of ctDNA testing. The framework takes into account the complete diagnostic workflow of ctDNA testing, including costs for personnel, materials, equipment, overhead, and failures. Evaluations and case studies were performed, showing a wide range of costs per sample and the sensitivity to platform, setting, and testing volume. An open access tool is provided for laboratory-specific calculations and exploring the total costs and impact of alternative prices or assumptions.
JOURNAL OF MOLECULAR DIAGNOSTICS
(2023)
Article
Biochemistry & Molecular Biology
Eline J. H. van Houtum, Esther D. Kers-Rebel, Maaike W. Looman, Erik Hooijberg, Christian Bull, Daniel Granado, Lenneke A. M. Cornelissen, Gosse J. Adema
Summary: Tumors create an immunosuppressive tumor microenvironment by altering protein expression and changing their glycosylation status, like altered expression of sialoglycans. Siglec-7, an inhibitory immune receptor similar to PD-1, is used by cancer cells as a glycoimmune checkpoint to evade the immune system. The exact cellular and molecular conditions required for Siglec-7-mediated immune cell inhibition remain largely unknown.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Article
Oncology
Hanne Lefrere, Kat Moore, Giuseppe Floris, Joyce Sanders, Iris M. Seignette, Tycho Bismeijer, Dennis Peters, Annegien Broeks, Erik Hooijberg, Kristel Van Calsteren, Patrick Neven, Ellen Warner, Fedro Alessandro Peccatori, Sibylle Loibl, Charlotte Maggen, Sileny N. Han, Katarzyna J. Jerzak, Daniela Annibali, Diether Lambrechts, Karin E. de Visser, Lodewyk Wessels, Liesbeth Lenaerts, Frederic Amant
Summary: Patients with postweaning postpartum breast cancer (PP-BCPW) have a poor prognosis compared with other types of breast cancer. This study found that PP-BCPW patients with low expression of immunoglobulin genes but high infiltration of plasma B cells have an increased risk of metastasis and death.
CLINICAL CANCER RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Robert S. Bresalier, Carlo Senore, Graeme P. Young, James Allison, Robert Benamouzig, Sally Benton, Patrick M. M. Bossuyt, Luis Caro, Beatriz Carvalho, Han-Mo Chiu, Veerle M. H. Coupe, Willemijn de Klaver, Clasine Maria de Klerk, Evelien Dekker, Sunil Dolwani, Callum G. Fraser, William Grady, Lydia Guittet, Samir Gupta, Stephen P. Halloran, Ulrike Haug, Geir Hoff, Steven Itzkowitz, Tim Kortlever, Anastasios Koulaouzidis, Uri Ladabaum, Beatrice Lauby-Secretan, Marcis Leja, Bernard Levin, Theodore Robert Levin, Finlay Macrae, Gerrit A. Meijer, Joshua Melson, Colm O'Morain, Susan Parry, Linda Rabeneck, David F. Ransohoff, Roque Saenz, Hiroshi Saito, Silvia Sanduleanu-Dascalescu, Robert E. Schoen, Kevin Selby, Harminder Singh, Robert J. C. Steele, Joseph J. Y. Sung, Erin Leigh Symonds, Sidney J. Winawer
Summary: New non-invasive tests for colorectal cancer (CRC) are emerging, making it challenging to conduct trials with mortality reduction as the main goal. A formal consensus approach involving experts resulted in the revision of previously established principles and the emergence of twelve new principles. The effectiveness of a new test can be evaluated by comparing it with an established non-invasive test, with the faecal immunochemical test considered as the appropriate comparator. Flexible adjustment of the new test's positivity threshold is desirable to meet different screening goals and requirements. A four-phased approach is proposed for the evaluation of new tests, including small studies, prospective estimation of accuracy, evaluation in screening populations, and monitoring for missed lesions.
Article
Oncology
Hielke M. de Vries, Tynisha S. Rafael, Alberto Gil-Jimenez, Jeantine M. de Feijter, Elise Bekers, Elsbeth van der Laan, Marta Lopez-Yurda, Erik Hooijberg, Annegien Broeks, Dennis Peters, Iris M. Seignette, Floris J. Pos, Simon Horenblas, Bas W. G. van Rhijn, Ekaterina S. Jordanova, Oscar R. Brouwer, Eva Schaake, Michiel S. van der Heijden
Summary: Atezolizumab shows significant antitumor activity in patients with advanced penile cancer, although the 1-year progression-free survival (PFS) did not meet the primary endpoint. Higher PFS is observed in patients with high-risk human papillomavirus-positive tumors and those with high infiltration of intratumoral CD3+CD8+ T cells.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Debra Van Egeren, Khushi Kohli, Jeremy L. Warner, Philippe L. Bedard, Gregory Riely, Eva Lepisto, Deborah Schrag, Michele LeNoue-Newton, Paul Catalano, Kenneth L. Kehl, Franziska Michor
Summary: The study found a significant association between TP53 mutations and distant metastasis in non-small cell lung cancer (NSCLC) patients, and TP53 mutations were more prevalent in patients with a history of smoking, suggesting a higher risk of distant metastasis in these patients.
SCIENTIFIC REPORTS
(2022)
Letter
Oncology
Iris van 't Erve, Cornelis J. A. Punt, Gerrit A. Meijer, Remond J. A. Fijneman
JCO PRECISION ONCOLOGY
(2022)